Miragen Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in discovering and developing proprietary RNA-targeted therapies with a specific focus on microRNAs and their role in diseases where there is a high unmet medical need. Its three lead product candidates include cobomarsen, an inhibitor of microRNA-155, which is in Phase I clinical trial for treating cutaneous T-cell lymphoma; MRG-201, a replacement for microRNA-29, which is in Phase I clinical trial that is found at low levels in various pathological fibrotic conditions, including cutaneous, cardiac, renal, hepatic, and pulmonary fibrosis, as well as systemic sclerosis; and MRG-110, an inhibitor of microRNA-92 that is expressed in endothelial cells and has shown to accelerate the formation of new blood vessels in preclinical models of heart failure, peripheral ischemia, and dermal wounding in the United States and Japan. The company also develops MRG-107, an inhibitor of miR-155 for treating neuronal amyotrophic lateral sclerosis, and other neurodegenerative indications, including spinal cord injury. It also develops preclinical product candidates for treating various indications, including oncology, visual pathologies, neurodegeneration, and hearing loss. Miragen Therapeutics, Inc. has a collaboration agreement with Les Laboratoires Servier and Institut de Recherches Servier for the development of MRG-110. The company was founded in 2006 and is based in Boulder, Colorado.
Industry, Sector and Symbol
Industry Medical laboratories
Sub-IndustryN/A
SectorMedical
Phone720-643-5200
Debt
Price-To-Earnings
Sales & Book Value
Annual Sales$4 million
Profitability
Miscellaneous
Employees65
OptionableNot Optionable
Miragen Therapeutics (NASDAQ:MGEN) Frequently Asked Questions
What is Miragen Therapeutics' stock symbol?
Miragen Therapeutics trades on the NASDAQ under the ticker symbol "MGEN."
How were Miragen Therapeutics' earnings last quarter?
Miragen Therapeutics Inc (NASDAQ:MGEN) posted its quarterly earnings results on Tuesday, August, 7th. The medical research company reported ($0.29) earnings per share for the quarter, hitting the Thomson Reuters' consensus estimate of ($0.29). The medical research company earned $2.18 million during the quarter, compared to analysts' expectations of $0.83 million. Miragen Therapeutics had a negative return on equity of 48.03% and a negative net margin of 316.11%. View Miragen Therapeutics' Earnings History.
When is Miragen Therapeutics' next earnings date?
What price target have analysts set for MGEN?
7 brokerages have issued 1-year target prices for Miragen Therapeutics' shares. Their forecasts range from $14.00 to $19.00. On average, they anticipate Miragen Therapeutics' stock price to reach $17.10 in the next year. This suggests a possible upside of 479.7% from the stock's current price. View Analyst Price Targets for Miragen Therapeutics.
What is the consensus analysts' recommendation for Miragen Therapeutics?
7 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Miragen Therapeutics in the last year. There are currently 1 hold rating and 6 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Miragen Therapeutics.
What are Wall Street analysts saying about Miragen Therapeutics stock?
Here are some recent quotes from research analysts about Miragen Therapeutics stock:
- 1. According to Zacks Investment Research, "Miragen Therapeutics, Inc. is a biopharmaceutical company. It develops microRNA biology, oligonucleotide chemistry, drugs and therapies for cancer, pathologic fibrosis, neuro-inflammatory and cardiovascular diseases. Miragen Therapeutics, Inc., formerly known as Signal Genetics, is headquartered in Boulder, Colorado. " (1/15/2019)
- 2. Wedbush analysts commented, "Athersys announced an expanded agreement with Helios KK (6927JP – NR) that includes additional indications and will bring in an additional $20M in capital to Athersys. In association with this deal, Dr. Hardy Kagimoto, CEO of Helios has been nominated for election (June 18, 2018) to the Athersys board of directors." (6/7/2018)
Has Miragen Therapeutics been receiving favorable news coverage?
News stories about MGEN stock have been trending neutral recently, InfoTrie Sentiment Analysis reports. InfoTrie ranks the sentiment of news coverage by analyzing more than six thousand blog and news sources. The firm ranks coverage of publicly-traded companies on a scale of negative five to five, with scores nearest to five being the most favorable. Miragen Therapeutics earned a news sentiment score of 0.2 on InfoTrie's scale. They also assigned press coverage about the medical research company a news buzz of 10.0 out of 10, meaning that recent news coverage is extremely likely to have an effect on the company's share price in the next several days.
Who are some of Miragen Therapeutics' key competitors?
Some companies that are related to Miragen Therapeutics include Celcuity (CELC), Enzo Biochem (ENZ), Psychemedics (PMD), PotNetwork (POTN), Fulgent Genetics (FLGT), First Choice Healthcare Solutions (FCHS), OpGen (OPGN), CBA Florida (CBAI), Cancer Genetics (CGIX), Aeon Global Health (AGHC), Biocept (BIOC) and Foundation Medicine (FMI).
Who are Miragen Therapeutics' key executives?
Miragen Therapeutics' management team includes the folowing people:
- Mr. Adam Scott Levy, Chief Bus. Officer (Age 41)
- Dr. Paul D. Rubin, Exec. VP of R&D (Age 65)
- Eric N. Olson, Co-Founder & Chairman of Scientific Advisory Board
- Dr. Michael R. Bristow, Co-Founder & Member of the Scientific Advisory Board (Age 74)
- Marvin H. Caruthers, Scientific Advisory Board Member (Age 79)
Who are Miragen Therapeutics' major shareholders?
Miragen Therapeutics' stock is owned by many different of retail and institutional investors. Top institutional shareholders include Atlas Venture Advisors Inc. (10.19%), 683 Capital Management LLC (5.50%), BlackRock Inc. (4.73%), Opaleye Management Inc. (1.25%), Geode Capital Management LLC (0.75%) and Dimensional Fund Advisors LP (0.70%). Company insiders that own Miragen Therapeutics stock include Adam Scott Levy, Bruce Booth, Kyle Lefkoff and Thomas E Hughes. View Institutional Ownership Trends for Miragen Therapeutics.
Which institutional investors are selling Miragen Therapeutics stock?
Which institutional investors are buying Miragen Therapeutics stock?
MGEN stock was purchased by a variety of institutional investors in the last quarter, including Atlas Venture Advisors Inc., 683 Capital Management LLC, D. E. Shaw & Co. Inc., BlackRock Inc., Bank of New York Mellon Corp, Geode Capital Management LLC, Rhumbline Advisers and Bank of America Corp DE. Company insiders that have bought Miragen Therapeutics stock in the last two years include Adam Scott Levy, Bruce Booth and Thomas E Hughes. View Insider Buying and Selling for Miragen Therapeutics.
How do I buy shares of Miragen Therapeutics?
Shares of MGEN can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Miragen Therapeutics' stock price today?
One share of MGEN stock can currently be purchased for approximately $2.95.
How big of a company is Miragen Therapeutics?
Miragen Therapeutics has a market capitalization of $90.98 million and generates $4 million in revenue each year. The medical research company earns $-26,510,000.00 in net income (profit) each year or ($1.38) on an earnings per share basis. Miragen Therapeutics employs 65 workers across the globe.
What is Miragen Therapeutics' official website?
How can I contact Miragen Therapeutics?
Miragen Therapeutics' mailing address is 6200 LOOKOUT ROAD, BOULDER CO, 80301. The medical research company can be reached via phone at 720-643-5200 or via email at [email protected]
MarketBeat Community Rating for Miragen Therapeutics (NASDAQ MGEN)
MarketBeat's community ratings are surveys of what our community members think about Miragen Therapeutics and other stocks. Vote "Outperform" if you believe MGEN will outperform the S&P 500 over the long term. Vote "Underperform" if you believe MGEN will underperform the S&P 500 over the long term. You may vote once every thirty days.
